Trang chủ / Tin tức / Khoa học & công nghệ
Khoa học & công nghệ

Dual mTORC1/2 and Scd1 inhibition uncovers a therapeutic vulnerability in pancreatic cancer

31/10/2026 · Thành viên: PGS.TS Nguyễn Chấn Hùng · Nguồn: OpenAlex

Hyperactivation of the mechanistic target of rapamycin (mTOR) complexes, mTORC1 and mTORC2, is common in pancreatic ductal adenocarcinoma (PDAC). However, clinical use of mTOR inhibitors has shown...

<p><strong>Tác giả:</strong> Chao Fang, Yuanyuan Yu, Yiping Yin, Zhao Shi, Zhaiyue Xu, Britta Statz, Yina Qiao, LI Hongzhen, Yifeng Sun, Jingxiong Hu, Tamer A. Abdelaal, Kathleen Schuck, Lei Wang, Thomas P. Hank, Max Heckler, Martin Loos, Ingrid Herr, Franco Fortunato, İhsan Ekin Demir, Helmut Friess, Shanshan Shen, Christoph W. Michalski, Bo Kong</p>

<p>Hyperactivation of the mechanistic target of rapamycin (mTOR) complexes, mTORC1 and mTORC2, is common in pancreatic ductal adenocarcinoma (PDAC). However, clinical use of mTOR inhibitors has shown limited efficacy due to rapid adaptive resistance. Using inducible genetically engineered mouse models and matched organoids, we delineated distinct complex-specific adaptations. Loss of mTORC1 delayed tumor progression but induced compensatory PI3K/Akt signalling hyperactivation, while concurrently...</p>

<p>📄 DOI: <a href="https://doi.org/https://doi.org/10.1038/s41388-026-04026-x" target="_blank" rel="noopener">https://doi.org/10.1038/s41388-026-04026-x</a></p>

<p>📖 <a href="https://doi.org/https://doi.org/10.1038/s41388-026-04026-x" target="_blank" rel="noopener">Xem bài báo đầy đủ</a></p>

Bài viết được biên soạn lại bởi LIFVietnam. Nguồn tham khảo: OpenAlex